Home › Research › Treatments
Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis
Jia Shang, Siyan Zhong, Li Shang, Qingze Zeng, Shuai Zhao, Xiao Luo, Kaicheng Li, Xinyi Zhang et al.. Alzheimer's research & therapy, 2025-11-17
Topic: Drug trials: efficacy and safety
Plain-language summary
The mean age was 66 years (65.53 ± 9.31), and 51 (67.1%) participants being female. A total of 49 (64.5%) participants were ApoE-ε4 carriers, including 34 (44.7%) heterozygotes and 15 (19.7%) homozygotes. Infusion-related side effects (IRSE), primarily occurred after the first infusion, were observed in 14 participants (18.4%). The most common IRSE were fever and fatigue. Until 9 Aug 2025, 58 participants had received treatment for more than 3 months, 44 for more than 6 months and 12 for more than 12 months. Amyloid-related imaging abnormalities (ARIA) were observed in 11 participants. Specifically, solitary ARIA-H (hemorrhage) was detected in 7 participants, while ARIA-E (edema) with or without cerebral micro-hemorrhage was identified in 4. Notably, all the 11 participants with ARIA were asymptomatic. Participants with isolated ARIA-H exhibited higher baseline Fazekas scores of PVWMHs (p = 0.008). Participants with a Clinical Dementia Rating Scale Global Score (CDR-GS) of 1 had a more rapid decline in Mini-Mental State Global Score (MMSE) scores as compared to those with a CDR-GS of 0.5. Following 12 months of lecanemab therapy, amyloid PET exhibited a significant reduction in brain amyloid burden. These data support that lecanemab appears to be generally tolerated in Asian population. The IRSE and ARIA-E events were less common than the Clarity AD study.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shang, J., Zhong, S., Shang, L., Zeng, Q., Zhao, S., Luo, X., et al. (2025). Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-025-01886-5
Vancouver
Shang J, Zhong S, Shang L, Zeng Q, Zhao S, Luo X, et al. Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis. Alzheimer's research & therapy. 2025. doi:10.1186/s13195-025-01886-5. PMID: 41250246.
BibTeX
@article{shang2025-41250246,
author = {Shang, Jia and Zhong, Siyan and Shang, Li and Zeng, Qingze and Zhao, Shuai and Luo, Xiao and Li, Kaicheng and Zhang, Xinyi and others},
title = {{Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis}},
journal = {Alzheimer's research \& therapy},
year = {2025},
doi = {10.1186/s13195-025-01886-5},
pmid = {41250246},
url = {https://doi.org/10.1186/s13195-025-01886-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The mean age was 66 years (65.53 ± 9.31), and 51 (67.1%) participants being female.
- A total of 49 (64.5%) participants were ApoE-ε4 carriers, including 34 (44.7%) heterozygotes and 15 (19.7%) homozygotes.
- Infusion-related side effects (IRSE), primarily occurred after the first infusion, were observed in 14 participants (18.4%).
- The most common IRSE were fever and fatigue.
- Until 9 Aug 2025, 58 participants had received treatment for more than 3 months, 44 for more than 6 months and 12 for more than 12 months.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Participants14
- Effect size67.1%; 64.5%; 44.7%
- Evidence strengthModerate
How this study scored 70/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 39 of the 56 points we could judge it on, which is 70 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 14 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41250246) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 39 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 39 of the 56 points we could judge it on is 70 out of 100. |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.